98%
921
2 minutes
20
Classical biological control (also called importation biological control) of weeds has a remarkable track record for efficiency and safety, but further improvement is still needed, particularly to account for potential evolutionary changes after release. Here, we discuss the increasing yet limited evidence of post-introduction evolution and describe approaches to predict evolutionary change. Recent advances include using experimental evolution studies over several generations that combine -omics tools with behavioral bioassays. This novel approach in weed biocontrol is well suited to explore the potential for rapid evolutionary change in real-time and thus can be used to estimate more accurately potential benefits and risks of agents before their importation. We outline this approach with a chrysomelid beetle used to control invasive common ragweed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cois.2020.02.006 | DOI Listing |
Circ Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
Crit Rev Toxicol
September 2025
Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
There is a concern on the safety of cosmetic ingredients and their endocrine-disrupting (ED) potential. Frequent use as well as the use of a diverse range of cosmetics pose a concern for a potential health risk via aggregate exposure to endocrine disrupting chemicals (EDCs). In this study, a list of ingredients available in cosmetic products that were recently introduced to the Dutch market was retrieved from the commercially accessible Mintel database and screened for the presence of EDCs.
View Article and Find Full Text PDFRev Med Liege
September 2025
Service de Chimie clinique, CHU Liège, Belgique.
Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD.
View Article and Find Full Text PDFJ Dance Med Sci
September 2025
Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
The aim of this study was to propose reference values for the Dynamic Evaluation Method of Lower Limb Joint Alignment (MADAAMI II). During the 2023 Joinville Dance Festival, 346 dancers (315 females and 31 males), aged between 15 and 58 years, with a minimum of 5 years of ballet experience, were randomly evaluated. The dancers were filmed performing the three-step sequence (demi plié, grand plié, and fondu) of the MADAAMI II, in the first foot position, with self-selected turnout and at 120 degrees.
View Article and Find Full Text PDFJ Med Internet Res
September 2025
Department of Precision Medicine, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands, 31 433883549.
Background: Making informed decisions about clinical trial participation can be overwhelming for patients due to the complexity of trial information, potential risks and benefits, and the emotional burden of a recent diagnosis. Patient decision aids (PDAs) simplify this process by providing clear information on treatment options, empowering patients to actively participate in shared decision-making with their doctors. While PDAs have shown promise in various health care contexts, their use in clinical trials, particularly in the form of trial-specific patient decision aids (tPDAs), remains underused.
View Article and Find Full Text PDF